Roles of HMGA proteins in cancer

Nature Reviews Cancer

Volumn 7, Issue 12, 2007, Pages 899-910

  Fusco, Alfredo ^a,b,c   Fedele, Monica ^a,b,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYCLIN A; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; HIGH MOBILITY GROUP A1C PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; APOPTOSIS; BENIGN TUMOR; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMATIN STRUCTURE; DNA REPAIR; DNA SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MESENCHYMOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; TUMOR CELL; WESTERN BLOTTING; WILD TYPE;

ADENOMA; ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HMGA PROTEINS; HUMANS; MESODERM; NEOPLASMS; ONCOGENES; PHENOTYPE; PITUITARY NEOPLASMS;

EID: 36448992338     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2271     Document Type: Review

References (155)

1. Johnson, K. R., Lehn, D. A. & Reeves, R. Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol. Cell Biol. 9, 2114-2123 (1989).
2. Nagpal, S. et al. Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J. Biol. Chem. 6, 22563-22568 (1999).
3. Reeves, R. & Nissen, M. S. The AT DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 265, 8573-8582 (1990).
4. Thanos, D. & Maniatis, T. The high mobility group protein HMG I(Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell 27, 777-789 (1992). The first paper describing the involvement of HMGA proteins as architectural factors in the assembly of a high-order multiprotein transcription complex.
5. Thanos, D., Du, W. & Maniatis, T. The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb. Symp. Quant. Biol. 58, 73-81 (1993).
6. Zhou, X., Benson, K. F., Ashar, H. R. & Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376, 771-774 (1995). This paper demonstrates that the spontaneous mouse pygmy phenotype, characterized by dwarfism that cannot be explained by aberrations in the growth hormone-insulin-like growth factor endocrine pathway, arises from the inactivation of the Hmga2 gene.
7. Chiappetta, G., et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13, 2439-2446 (1996).
8. Rogalla, P. et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am. J. Pathol. 149, 775-779 (1996).
9. Rommel, B. et al. HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk. Lymphoma. 26, 603-607 (1997).
10. Anand, A. & Chada K. In vivo modulation of Hmgic reduces obesity. Nature Genet. 24, 377-380 (2000).
11. Chieffi, P. et al. HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene 21, 3644-3650 (2002).
12. Di Agostino, S. et al. Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. Mol. Biol. Cell 15, 1224-1232 (2004).
13. Giancotti, V. et al. Changes in nuclear proteins following transformation of rat thyroid epithelial cells by a murine sarcoma retrovirus. Cancer Res. 45, 6051-6057 (1985). First isolation of the HMGA2 protein and association of HMGA protein expression with the neoplastic phenotype.
14. Giancotti, V. et al. Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp. Cell Res. 184, 538-545 (1989).
15. Chiappetta, G. et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10, 1307-1314 (1995).
16. Lund, T., Holtlund, J., Fredriksen, M. & Laland, S. G. On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett. 21, 163-167 (1983).
17. Giancotti, V. et al. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c- myc and polyoma middle T genes. EMBO J. 6, 1981-1987 (1987).
18. Berlingieri, M. T. et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell Biol. 15, 1545-1553 (1995). By using an antisense technology to block HMGA2 protein synthesis, this paper demonstrates the causal role of HMGA proteins in thyroid cell transformation induced by retroviral transforming oncogenes.
19. Berlingieri, M. T., Pierantoni, G. M., Giancotti, V., Santoro, M. & Fusco, A. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21, 2971-2980 (2002).
20. Scala, S., Portella, G., Fedele, M., Chiappetta, G. & Fusco, A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl Acad. Sci. USA. 97, 4256-4261 (2000).
21. Fedele, M. et al. Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res. 61, 4583-4590 (2001).
22. Wood, L. J., Maher, J. F., Bunton, T. E. & Resar, L. M. The oncogenic properties of the HMG-I gene family. Cancer Res. 60, 4256-4261 (2000). This paper demonstrates that overexpression of the HMGA1 and HMGA2 proteins can transform cells in culture.
23. Reeves, R., Edberg, D. D. & Li, Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell Biol. 21, 575-594 (2001). Human breast epithelial cells harboring tetracycline-regulated HMGI(Y) transgenes acquire the ability to form both primary and metastatic tumours in nude mice only when the transgenes are actively expressed. Many of these tumors have undergone an epithelial-mesenchymal transition in vivo. The HMGA1b, rather than the HMGA1a, isoform of these proteins is the most effective elicitor of both neoplastic transformation and metastatic progression.
24. Sreekantaiah, C. et al. Cytogenetic profile of 109 lipomas. Cancer Res. 51, 422-433 (1991).
25. Schoenmakers, E. F., et al. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nature Genet. 10, 436-444 (1995).
26. Ashar, H. R. et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82, 57-65 (1995). References 25 and 26 report, for the first time, rearrangements of the HMGA2 gene in benign mesenchymal tumours.
27. Heim, S. et al. A specific translocation, t (12;14) (q14-15;q23-24), characterizes a subgroup of uterine leiomyomas. Cancer Genet. Cytogenet. 32, 13-17 (1988).
28. Hennig, Y. et al. HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality. Cancer Genet. Cytogenet. 96, 129-133 (1997).
29. Kazmierczak, B. et al. HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. Oncogene 12, 515-521 (1996).
30. Staats, B. et al. A fibroadenoma with a t(4;12) (q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein gene family. Breast Cancer Res. Treat. 38, 299-303 (1996).
31. Walter, T. A., Fan, S. X., Medchill, M. T., Berger, C. S. Decker, H. J. & Sandberg, A. A. Inv (12) (p11. q13) in an endometrial polyp. Cancer Genet. Cytogenet. 41, 99-103 (1989).
32. Wanschura, S., et al. Hidden paracentric inversions of chromosome arm 12q affecting the HMGIC gene. Genes Chromosomes Cancer 18, 322-323 (1997).
33. Dal Cin, P. et al. Amplification and expression of the HMGIC gene in a benign endometrial polyp. Genes Chromosomes Cancer 22, 95-99 (1998).
34. Wanschura, S. et al. Regional fine mapping of the multiple-aberration region involved in uterine leiomyoma, lipoma and pleomorphic adenoma of the salivary gland to 12q15. Genes Chromosomes Cancer 14, 68-70 (1995).
35. Geurts, J. M., Schoenmakers, E. F., Roijer, E., Astrom, A. K., Stenman, G. & Van de Ven, W. J. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 16, 865-872 (1998).
36. Geurts, J. M., Schoenmakers, E. F., Roijer, E., Stenman, G. & Van de Ven, W. J. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res. 57, 13-17 (1997).
37. Geurts, J. M., Schoenmakers, E. F. & Van de Ven, W. J. Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3′-UTR of HMGIC. Cancer Genet. Cytogenet. 95, 198-205 (1997).
38. Rabban, J. T., Dal Cin, P. & Oliva, E. HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma. Int. J. Gynecol. Pathol. 25, 403-407 (2006).
39. Kazmierczak, B. et al. Molecular characterization of 12q14-15 rearrangements in three pulmonary chondroid hamartomas. Cancer Res. 55, 2497-2499 (1995).
40. Kools, P. F. & Van de Ven, W. J. Amplification of a rearranged form of the high-mobility group protein gene HMGI-C in OsA-CI osteosarcoma cells. Cancer Genet. Cytogenet. 91, 1-7 (1996).
41. Mine, N. et al. Fusion of a sequence from HEI10 (14q11) to the HMGIC gene at 12q15 in a uterine leiomyoma. Jpn J. Cancer Res. 92, 135-139 (2001).
42. Schoenmakers, E. F., Huysmans, C. & Van de Ven, W. J. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res. 59, 19-23 (1999).
43. Nielsen, G. P. & Mandahl, N. Lipoma. In World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone (eds Fletcher, C. D. M., Unni, K. K. & Mertens, F.) 19-46 (IARC Press, Lyon, 2002).
44. Petit, M. M. R., Mols, R., Schoenmakers, E. F., Mandahl, N. & Van de Ven W. J. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 36, 118-129 (1996).
45. Lemke, I., Rogalla, P. & Bullerdiek, J. A novel LPP fusion gene indicates the crucial role of truncated LPP proteins in lipomas and pulmonary chondroid hamartomas. Cytogenet. Cell Genet. 95, 153-156 (2001).
46. Fedele, M. et al. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 17, 413-418 (1998).
47. Lee, Y. S. & Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21, 1025-1030 (2007).
48. Mayr, C., Hemmann, M. T. & Bartel, D. P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579 (2007). References 47 and 48 demonstrate that HMGA2 expression is downregulated by let-7 miRNA.
49. Hebert, C., Norris, K., Scheper, M. A., Nikitakis, N. & Sauk, J. J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Molecular Cancer 6, 5-16 (2007).
50. Wang, T. et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46, 336-347 (2007).
51. Borrmann, L., Wilkening, S. & Bullerdiek, J. The expression of HMGA genes is regulated by their 3?UTR. Oncogene 20, 4537-4541 (2001).
52. Battista, S. et al. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res. 59, 4793-4797 (1999).
53. Arlotta, P. et al. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J. Biol. Chem. 275, 14394-14400 (2000).
54. Fedele, M. et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21, 3190-3198 (2002).
55. Zaidi, M. R., Okada, Y. & Chada, K. K. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res. 66, 7453-7459 (2006).
56. Ligon, A. H. et al. Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. Am. J. Hum. Genet. 76, 340-348 (2005).
57. Tallini, G. et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab. Invest. 80, 359-369 (2000).
58. Sornberger, K. S. et al. Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet. Cytogenet. 114, 9-16 (1999).
59. Kazmierczak, B. et al. A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. Genes Chromosomes Cancer 26, 125-133 (1999).
60. Rohen, C. et al. Pleomorphic adenomas of the salivary glands: absence of HMGIY rearrangements. Cancer Genet. Cytogenet. 111, 178-181 (1999).
61. Kazmierczak, B. et al. HMGY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Gene Chromosomes Cancer 23, 279-285 (1998).
62. Rogalla, P., Blank, C., Helbig, R., Wosniok, W. & Bullerdiek, J. Significant correlation between the breakpoints of rare clonal aberrations in benign solid tumors and the assignment of HMGIY retropseudogenes. Cancer Genet. Cytogenet. 130, 51-56 (2001).
63. Finelli, P. et al. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res. 62, 2398-2405 (2002).
64. Pierantoni, G. M. et al. High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr. Relat. Cancer 12, 867-874 (2005).
65. Bettio, D. et al. Cytogenetic study of pituitary adenomas. Cancer Genet. Cytogenet. 98, 131-136 (1997).
66. Finelli, P. et al. Non random trisomies of chromosomes 5, 8 and 12 in the prolactinoma subtype of pituitary adenomas: conventional cytogenetics and interphase FISH study. Int. J. Cancer 86, 344-350 (2000).
67. Fedele, M. et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer lymphomas. Oncogene 24, 3427-3435 (2005).
68. Bussemakers, M. J. G., Van de Ven, W. J. M., Debruyne, F. M. J. & Schalken, J. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res. 51, 606-611 (1991).
69. Tamimi, Y. et al. Increased expression of high mobility group protein I (Y) in high grade prostate cancer detemined by in situ hybridization. Cancer Res. 53, 5512-5516 (1993).
70. Abe, N. et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 60, 3117-3122 (2000).
71. Abe, N. et al. Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. Pancreas 25, 198-204 (2002).
72. Chiappetta, G. et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 58, 4193-4198 (1998).
73. Kim, S. J., Ryu, J. W. & Choi, D. S. The expression of the high mobility group I(Y) mRNA in thyroid cancers: useful tool of differential diagnosis of thyroid nodules. Korean J. Intern. Med. 15, 71-75 (2000).
74. Fedele, M. et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res. 56, 1896-1901 (1996).
75. Abe, N. et al. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res. 59, 1169-1174 (1999).
76. Chiappetta, G. et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int. J. Cancer 91, 147-151 (2001).
77. Balcerczak, M. et al. HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging. Pathol. Res. Pract. 199, 641-646 (2003).
78. Flohr, A. M. et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol. Histopathol. 18, 999-1004 (2003).
79. Chiappetta, G. et al. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin. Cancer Res. 10, 7637-7644 (2004).
80. Sarhadi, V. K. et al. Increased expression of high mobility group A proteins in lung cancer. J. Pathol. 209, 206-212 (2006).
81. Masciullo, V. et al. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24, 1191-1198 (2003).
82. Bandiera, A. et al. Expression of high mobility group I (HMGI) proteins in squamous intraepithelial lesions (SILs) of uterine cervix. Cancer Res. 58, 426-431 (1998).
83. Tesfaye, A. et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res. 67, 3998-4004 (2007).
84. Nam, E. S. et al. Expression of HMGI(Y) associated with malignant phenotype of human gastric tissue. Histopathology 42, 466-471 (2003).
85. Rho, Y. S. et al. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol. 127, 76-81 (2007).
86. Abe, N. et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br. J. Cancer 89, 2104-2109 (2003).
87. Meyer, B. et al. HMGA2 overexpression in non-small cell lung cancer. Mol. Carcinog. 46, 503-511 (2007).
88. Miyazawa, J., Mitoro, A., Kawashiri, S., Chada, K. K. & Imai, K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 64, 2024-2029 (2004).
89. Franco, R. et al. Detection of high mobility group proteins A1 and A2 represents a valid diagnostic marker in testicular germ cell tumors. J. Pathol. (in the press).
90. Donato, G. et al. High mobility group A1 expression correlates with the histological grade of human glial tumors. Oncol. Rep. 11, 1209-1213 (2004).
91. Akai, T. et al. High mobility group I-C protein in astrocytoma and glioblastoma. Pathol. Res. Pract. 200, 619-624 (2004).
92. Abe, N. et al. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. J. Gastroenterol. 38, 1144-1149 (2003).
93. Chuma, M. et al. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J. Med. 53, 90-97 (2004).
94. Chang, Z. G. et al. Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig. Dis. Sci. 50, 1764-1770 (2005).
95. Cleynen, I. et al. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression. Cancer Res. 15, 4620-4629 (2007).
96. Pierantoni, G. M. et al. High mobility group A1 proteins are overexpressed in human leukemias. Biochem. J. 372, 145-150 (2003).
97. Santulli, L. et al. A 12q13 translocation involving the HMGI-C gene in one case of Richter's transformation of a chronic lymphocytic leukaemia. Cancer Genet. Cytogenet. 119, 70-73 (2000).
98. Pierantoni, G. M. et al. HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. Int. J. Oncol. 22, 363-367 (2003).
99. Andrieux, J. et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39, 82-87 (2004).
100. Andrieux, J. et al. Cryptic 6p21.3 duplications and triplication involving HMGA1 partially masked by add 6p in four cases of myelodysplasia. Cancer Gene Cytogenet. 164, 84-87 (2006).
101. Odero, M. D. et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia 19, 245-252 (2005).
102. Wood, L. J. et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol. Cell Biol. 20, 5490-5502 (2000).
103. Baldassarre, G. et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc. Natl Acad. Sci. USA. 98, 7970-7975 (2001).
104. Xu, Y. et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res. 64, 3371-3375 (2004).
105. Fedele, M. et al. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelolymphoproliferative disorders in mice. Cancer Res. 66, 2536-2543 (2006). Describes the generation of knockout mice for the Hmga1 gene and demonstrates in vivo its potential tumour suppressor role.
106. Narita, M. et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126, 503-514 (2006). Demonstrates that HMGA proteins are essential structural components of the senescence machinery, implying that they also act in tumour suppressor networks.
107. Li, Y., Lu, J. & Prochownik E. V. Dual role for for SUMO E2 conjugase Ubc9 in modulating the transforming and growth-promoting properties of the HMGA1b architectural transcription factor. J. Biol. Chem. 282, 13363-13371 (2007).
108. Evan, G. I., Brown, L., Whyte, M. & Harrington, E. Apoptosis and the cell cycle. Curr. Opin. Cell Biol. 7, 825-834 (1995).
109. Seville, L. L., Shah, N., Westwell, A. D. & Chan, W. C. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr. Cancer Drug Targets. 5, 159-170 (2005).
110. Fedele, M. et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9, 459-471 (2006). This paper describes a mechanism, dependent on the binding of HMGA2 to the Retinoblastoma protein, by which HMGA2 activates E2F1 and induces pituitary adenomas in mice.
111. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. & Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J. 11, 961-971 (1992).
112. Tessari, M. A. et al. Transcriptional activation of the cyclin A gene by architectural transcriptional factor HMGA2. Mol. Cell Biol. 23, 9104-9116 (2003).
113. Angel, P. & Karin, M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim. Biophys. Acta 1072, 129-157 (1991).
114. Karin, M., Liu, Z. & Zandi, E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9, 240-246 (1997).
115. Vallone, D. et al. Neoplastic transformation of rat thyroid cells requires the JunB and Fra1 gene induction which is dependent on the HMGI-C gene products. EMBO J. 17, 5310-5321 (1997).
116. Casalino, L. et al. Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J. 26, 1878-1890 (2007).
117. Chiappetta, G. et al. FRA-1 protein detection is associated with thyroid proliferative disorders. Clin. Cancer Res. 6, 4300-4306 (2000).
118. Chiappetta, G. et al. FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 7, 17 (2007).
119. Dhar, A., Hu, J., Reeves, R., Resar, L. M.& Colburn, N. H. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 23, 4466-4476, (2004).
120. Hommura, F. et al. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol. Cancer Res. 2, 305-314 (2004).
121. Pierantoni, G. M. et al. High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ. 13, 1554-1563 (2006).
122. Frasca, F. et al. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res. 66, 2980-2989 (2006).
123. Pierantoni, G. M. et al. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J. Clin. Invest. 117, 693-702 (2007). Describes a novel mechanism through which HMGA1 could exert its oncogenic activity: HMGA1 inhibits p53-mediated apoptosis by promoting cytoplasmic relocalization of the p53 proapoptotic activator HIPK2.
124. Subramanian, D. & Griffith, J. D. Interactions between p53, hMSH2-hMSH6 and HMGI(Y) on Holliday junctions and bulged bases. Nucleic Acids Res. 30, 2427-2434 (2002).
125. Reeves, R. & Adair, J. E. Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA Repair 4, 926-938 (2005).
126. Borrmann, L. et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res. 31, 6841-6851 (2003).
127. Baldassarre, G. et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell Biol. 23, 2225-2238 (2003).
128. Baldassarre, G. et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 24, 6809-6819 (2005).
129. Boo, L. M. et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res. 65, 6622-6630 (2005).
130. Muller-Tidow, C. et al. The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol. Cell Biol. 24, 8917-8928 (2004).
131. Mantovani, A. Cancer: inflammation by remote control. Nature 435, 752-753 (2005).
132. Perrella, M. A. et al. High mobility group-I(Y) protein facilitates nuclear factor-κB binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer. J. Biol. Chem. 274, 9045-9052 (1999).
133. Ji, Y. S., Xu, Q. & Schmedtje, J. F. Jr. Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ. Res. 83, 295-304 (1998).
134. Whitley, M. Z., Thanos, D., Read, M. A., Maniatis, T. & Collins, T. A striking similarity in the organization of the E-selectin and β interferon gene promoters. Mol. Cell Biol. 14, 6464-6475 (1994).
135. Kim, J., Reeves, R., Rothman, P. & Boothby, M. The non-histone chromosomal protein HMG-I(Y) contributes to repression of the immunoglobulin heavy chain germ-line epsilon RNA promoter. Eur. J. Immunol. 25, 798-808 (1995).
136. Chuvpilo, S. et al. Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter. Nucleic Acids Res. 21, 5694-5704 (1993).
137. Himes, S. R., Coles, L. S., Reeves, R. & Shannon, M. F. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity 5, 479-489 (1996).
138. Kim, H. P., Kelly, J. & Leonard, W. J. The basis for IL-2-induced IL-2 receptor α chain gene regulation: importance of two widely separated IL-2 response elements. Immunity 15, 159-172 (2001).
139. Mantovani, F. et al. NF-κB mediated transcriptional activation is enhanced by the architectural factor HMGI.-C. Nucleic Acids Res. 26, 1433-1439 (1998).
140. Zhang, X. M. & Verdine, G. L. A small region in HMG I(Y) is critical for cooperation with NF-κB on DNA. J. Biol. Chem. 274, 20235-20243 (1999).
141. Bogdan, C. Nitric oxide and the immune response. Nature Immunol. 2, 907-916 (2001).
142. Geller, D. A. & Billiar, T. R. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev. 17, 7-23 (1998).
143. Tsujii, M., Kawano, S. & DuBois, R. N. Cycloxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 94, 3336-3340 (1997).
144. Huber, M. A., Kraut, N. & Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17, 548-558 (2005).
145. Thuault, S., Valcourt, U., Petersen, M., Manfioletti. G., Heldin, C. H. & Moustakas, A. Transforming growth factor-β employs HMGA2 to elicit epithelialmesenchymal transition. J. Cell Biol. 174, 175-183 (2006).
146. Pallante, P. et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13, 497-508 (2006).
147. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA. 103, 2257-2261 (2006).
148. Langelotz, C. et al. Expression of high-mobilitygroup-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br. J. Cancer 88, 1406-1410 (2003).
149. Trapasso, F. et al. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther. 11, 633-641 (2004).
150. Liau, S. S., Jazag, A. & Whang, E. E. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 66, 11613-11622 (2006).
151. Chin, M. T. et al. Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J. Biol. Chem. 27, 9755-9760 (1998).
152. Galande, S. Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. Curr. Cancer Drug Targets 2, 157-190 (2002).
153. Zhao, K., Käs, E., Gonzalez, E. & Laemmli, U. K. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J. 12, 3237-3247 (1993).
154. Foti, D. et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nature Med. 11, 765-773 (2005).
155. D'Orazi, G. et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biol. 4, 11-19 (2002).